{
    "eid": "2-s2.0-85070812992",
    "title": "BRCA mutation in high grade epithelial ovarian cancers",
    "cover-date": "2019-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Obstetrics and Gynecology",
            "@code": "2729",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "BRCA mutation",
        "Epithelial ovarian cancer",
        "High grade endometrioid carcinoma",
        "High grade serous carcinoma"
    ],
    "authors": [
        "Tarinee Manchana",
        "Natacha Phoolcharoen",
        "Patou Tantbirojn"
    ],
    "citedby-count": 44,
    "ref-count": 22,
    "ref-list": [
        "BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group",
        "Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review",
        "Integrated genomic analyses of ovarian carcinoma",
        "Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer",
        "High-risk epithelial ovarian cancer patients for hereditary ovarian cancer",
        "Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients: finding founder mutations",
        "Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube",
        "PARP inhibitors in ovarian cancer: evidence, experience and clinical potential",
        "Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients",
        "Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates",
        "Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer",
        "Homologous recombination deficiency and ovarian cancer",
        "Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations",
        "BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients",
        "BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing",
        "Survival outcomes for different subtypes of epithelial ovarian cancer",
        "BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases",
        "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology",
        "Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment",
        "BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer",
        "The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients",
        "Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60022183",
        "affilname": "King Chulalongkorn Memorial Hospital",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
        "affiliation-country": "Thailand"
    },
    "funding": []
}